Plavix generic now available - May 17, 2012

[Anonymous]

Available in U.S.

 

[Anonymous]

Good and bad. Bad for retail but where restrictions to the Lilly contract only allowed two barnd ADPs, Brilinta might gain some more hospital wins and even push Effient off the map.

 

[Anonymous]

Good and bad. Bad for retail but where restrictions to the Lilly contract only allowed two barnd ADPs, Brilinta might gain some more hospital wins and even push Effient off the map.

Good points. I hope for the latter.

 

[Anonymous]

It is about time. I think it is a great thing that will save a lot of people money. My Dad has been taking it for a couple of years and it was expensive. Its great news for many of us.

 

[Anonymous]

Cardiologists have openly pointed out that a generic Plavix is not the best news for people who have had an angioplasty. Legally, you can be +/- 20% of the bio-equivalence of the original molecule to bring a generic to market. That's acceptable if it's an ACE inhibitor that might make you cough and you can just switch it out for another pill, or class even - this is relatable to statins, derm products, etc. etc. When you are speaking about the avoidance of thrombotic events after a stent, bleeding and re-operation due to hypo/hyper response, it makes sense to have a predictable and quality controlled agent in the acute care setting. Once the patient hits the pharmacy a few months out, that's a different story all together. They will get letters from the pharmacy and the payor asking them if they were aware of a generic in the same class, etc. Truth be told, that for the long-term, aspirin has the best data for events and get's the lion's share of guideline approaches. DAPT gets you through the acute stages and should be aggressive by all counts. Ticagrelor has a significant benefit, but the payor mix and managed care support is atrocious and that's routinely brought up because we're not going to get paid on wholesale data.

 

[Anonymous]

The +/-20% bio-equivalence is the stuff big Pharma marketing departments like to tout. While a handful of prescribers may be sensitive to any differences, it is a small percentage overall. On the other hand reduced costs provide enormous savings for patients and third party payers, and drug tiers usually reflect this.

The Pharmacist's Letter still recommends Plavix first, especially when the generic becomes available.

 

[Anonymous]

The +/-20% bio-equivalence is the stuff big Pharma marketing departments like to tout. While a handful of prescribers may be sensitive to any differences, it is a small percentage overall. On the other hand reduced costs provide enormous savings for patients and third party payers, and drug tiers usually reflect this.

The Pharmacist's Letter still recommends Plavix first, especially when the generic becomes available.

The generic IS available smart one.....

 

[Anonymous]

I will always ask for generics before brand drugs. Only if there is a clear advantage of efficacy or side effects. Often nowadays there is little difference. Generics will always win. Industry over!